The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review

Wu, Qinchao; Bai, Baochen; Tian, Chao; Li, Daisong; Yu, Hua; Song, Bingxue; Li, Bing; Chu, Xiangcheng

doi:10.1007/s10557-021-07181-3

Cited by 29 publications

(26 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Baseline electrocardiograms (ECGs) should be obtained which will evaluate the risk of arrhythmia. Myoglobin (MYO), B-type natriuretic peptide (BNP), and other biochemical indexes should be obtained and corrected (85)(86)(87).…”

Section: Managementmentioning

confidence: 99%

“…Second, electrolytes should be monitored, especially Na + , K + , and Ca 2+ which have an influence on heart rhythm. Abnormal electrolytes will be a potential risk of arrhythmia and should be corrected immediately (87,88).…”

Section: Managementmentioning

confidence: 99%

“…Fifth, after taking medicine, if a faint, headache, or irregular heartbeat occurs, healthcare should be provided immediately. The decision of heart rate or rhythm control should be patient-centered and symptom-oriented (87), beta-blockers may be the first choice for heart rate control, and type Ic and type III antiarrhythmic drugs are helpful for heart rhythm (87,91).…”

Section: Managementmentioning

confidence: 99%

See 2 more Smart Citations

Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies

Cheng

Yang

Liu

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

With the development of anti-tumor drugs, tyrosine kinase inhibitors (TKIs) are an indispensable part of targeted therapy. They can be superior to traditional chemotherapeutic drugs in selectivity, safety, and efficacy. However, they have been found to be associated with serious adverse effects in use, such as myocardial infarction, fluid retention, hypertension, and rash. Although TKIs induced arrhythmia with a lower incidence than other cardiovascular diseases, much clinical evidence indicated that adequate attention and management should be provided to patients. This review focuses on QT interval prolongation and atrial fibrillation (AF) which are conveniently monitored in clinical practice. We collected data about TKIs, and analyzed the molecule mechanism, discussed the actual clinical evidence and drug-drug interaction, and provided countermeasures to QT interval prolongation and AF. We also pooled data to show that both QT prolongation and AF are related to their multi-target effects. Furthermore, more than 30 TKIs were approved by the FDA, but most of the novel drugs had a small sample size in the preclinical trial and risk/benefit assessments were not perfect, which led to a suspension after listing, like nilotinib. Similarly, vandetanib exhibits the most significant QT prolongation and ibrutinib exhibits the highest incidence in AF, but does not receive enough attention during treatment.

show abstract

Section: Managementmentioning

confidence: 99%

Section: Managementmentioning

confidence: 99%

Section: Managementmentioning

confidence: 99%

See 1 more Smart Citation

Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies

Cheng

Yang

Liu

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Similar to mRNAs, most lncRNAs are transcribed by RNA polymerase II (Pol II), capped at the 5 ′ end (m7G), tailed at the 3 ′ end (polyadenylation) and spliced, but lncRNAs lack an open reading frame and do not encode proteins for translation (10). According to the positional relationship between lncRNAs and protein-coding genes, lncRNAs can be divided into (1) sense lncRNAs that overlap with protein-coding genes; (2) antisense lncRNAs that are opposite to protein-coding genes; (3) lncRNAs from introns of protein-coding genes; (4) intergenic lncRNAs located between protein-coding genes; (5) lncRNAs derived from enhancers of protein-coding genes; (6) divergent lncRNAs transcribed from bidirectional promoters; and (7) circular RNAs (circRNAs) formed by the reverse splicing of protein-coding genes (11,12). LncRNAs are located in the nucleus and cytoplasm and participate in the regulation of gene transcription through cis-acting or trans-acting mechanisms (10,(13)(14)(15).…”

Section: Lncrna Classification and Functionmentioning

confidence: 99%

“…In the case of myocardial infarction, emergency PCI or thrombolytic therapy can save the life of the patient but cannot block the adverse progression of the ischemic myocardium. For cancer patients, chemotherapeutic interventions can easily lead to premature heart failure (2). Therefore, exploring the molecular mechanisms underlying CVD and developing new treatments are critical for reducing CVD mortality.…”

Section: Introductionmentioning

confidence: 99%

New Developments in Exosomal lncRNAs in Cardiovascular Diseases

Yuan

Huang

2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are non-coding RNAs with lengths >200 nt and are involved in the occurrence and development of cardiovascular diseases (CVDs). Exosomes are secreted and produced by various cell types. Exosome contents include various ncRNAs, proteins and lipids. Exosomes are also important mediators of intercellular communication. The proportion of lncRNAs in exosomes is low, but increasing evidence suggests that exosomal lncRNAs play important roles in CVDs. We focused on research progress in exosomal lncRNAs in atherosclerosis, myocardial infarction, myocardial ischemia-reperfusion injury, cardiac angiogenesis, cardiac aging, rheumatic heart disease, and chronic kidney disease combined with CVD. The potential diagnostic and therapeutic effects of exosomal lncRNAs in CVDs are summarized based on preclinical studies involving animal and cell models and circulating exosomes in clinical patients. Finally, the challenges and possible prospects of exosomes and exosomal lncRNAs in clinical applications related to CVD are discussed.

show abstract

Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer

et al. 2022

View full text Add to dashboard Cite

The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review

Cited by 29 publications

References 145 publications

Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies

Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies

New Developments in Exosomal lncRNAs in Cardiovascular Diseases

Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer

Contact Info

Product

Resources

About